RAB5A and breast carcinoma: Moreover, the expressed amounts of RAB5 and RAB27A in breast cancer cells (Fig. 3d) and SK-MEL-28 melanoma cells (Supplementary Fig. 9b) were significantly reduced after treatment with SFX in a dose-dependent manner.